Loading…

Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2022-01, Vol.17 (10)
Main Authors: Yi-Lin Chang, Ya-Fu Cheng, Hui-Shan Chen, Siao-Chi Wu, Wei-Heng Hung, Heng-Chung Chen, Chang-Lun Huang, Ching-Yuan Cheng, Bing-Yen Wang
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 10
container_start_page
container_title PloS one
container_volume 17
creator Yi-Lin Chang
Ya-Fu Cheng
Hui-Shan Chen
Siao-Chi Wu
Wei-Heng Hung
Heng-Chung Chen
Chang-Lun Huang
Ching-Yuan Cheng
Bing-Yen Wang
description Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Results Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p
format article
fullrecord <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b</doaj_id><sourcerecordid>oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b</sourcerecordid><originalsourceid>FETCH-doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b3</originalsourceid><addsrcrecordid>eNqtjklOxTAQRCMkJD7DHfoCX3IGDFkjEOxYsI86difpyBO2k6-cjOsRMexYsiqpVK-qzopD2dbVUVaiviguU5qFuK3vpTwUH6_RB3KJ8wZJ-UiADs2WOIHyNmBkN0Ja4sorGugpn4gcaBrYceaVQE1kfUTNPk8UMWx7gQZKPkw4ksrebnDiPAHqeVnR5T8IdhAwM7mcvrO_-D6Z3he0ftnvkDGgMCp23uJ1cT6gSXTzo1fFy9Pj28PzUXucuxDZYtw6j9x9GT6OHcbMylCnVKPLVlJLom1UKfqq6fFOyrIVwyBFX_9n1yfVmYJN</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Yi-Lin Chang ; Ya-Fu Cheng ; Hui-Shan Chen ; Siao-Chi Wu ; Wei-Heng Hung ; Heng-Chung Chen ; Chang-Lun Huang ; Ching-Yuan Cheng ; Bing-Yen Wang</creator><creatorcontrib>Yi-Lin Chang ; Ya-Fu Cheng ; Hui-Shan Chen ; Siao-Chi Wu ; Wei-Heng Hung ; Heng-Chung Chen ; Chang-Lun Huang ; Ching-Yuan Cheng ; Bing-Yen Wang</creatorcontrib><description>Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Results Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p&lt;0.0001). In multivariable analysis, treatment modality was an independent prognostic factor. Esophagectomy with adjuvant chemoradiotherapy provided better survival outcome than definitive chemoradiotherapy for patients with clinical stage II/III disease. As for patients with clinical stage I disease, there was no significant survival difference between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy. Conclusions Esophagectomy with adjuvant chemoradiotherapy provided better survival than definitive chemoradiotherapy in clinical II/III esophageal squamous cell carcinoma. However, more data are needed to conduct a convincing conclusion in clinical stage I patients.</description><identifier>EISSN: 1932-6203</identifier><language>eng</language><publisher>Public Library of Science (PLoS)</publisher><ispartof>PloS one, 2022-01, Vol.17 (10)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Yi-Lin Chang</creatorcontrib><creatorcontrib>Ya-Fu Cheng</creatorcontrib><creatorcontrib>Hui-Shan Chen</creatorcontrib><creatorcontrib>Siao-Chi Wu</creatorcontrib><creatorcontrib>Wei-Heng Hung</creatorcontrib><creatorcontrib>Heng-Chung Chen</creatorcontrib><creatorcontrib>Chang-Lun Huang</creatorcontrib><creatorcontrib>Ching-Yuan Cheng</creatorcontrib><creatorcontrib>Bing-Yen Wang</creatorcontrib><title>Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma</title><title>PloS one</title><description>Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Results Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p&lt;0.0001). In multivariable analysis, treatment modality was an independent prognostic factor. Esophagectomy with adjuvant chemoradiotherapy provided better survival outcome than definitive chemoradiotherapy for patients with clinical stage II/III disease. As for patients with clinical stage I disease, there was no significant survival difference between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy. Conclusions Esophagectomy with adjuvant chemoradiotherapy provided better survival than definitive chemoradiotherapy in clinical II/III esophageal squamous cell carcinoma. However, more data are needed to conduct a convincing conclusion in clinical stage I patients.</description><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqtjklOxTAQRCMkJD7DHfoCX3IGDFkjEOxYsI86difpyBO2k6-cjOsRMexYsiqpVK-qzopD2dbVUVaiviguU5qFuK3vpTwUH6_RB3KJ8wZJ-UiADs2WOIHyNmBkN0Ja4sorGugpn4gcaBrYceaVQE1kfUTNPk8UMWx7gQZKPkw4ksrebnDiPAHqeVnR5T8IdhAwM7mcvrO_-D6Z3he0ftnvkDGgMCp23uJ1cT6gSXTzo1fFy9Pj28PzUXucuxDZYtw6j9x9GT6OHcbMylCnVKPLVlJLom1UKfqq6fFOyrIVwyBFX_9n1yfVmYJN</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Yi-Lin Chang</creator><creator>Ya-Fu Cheng</creator><creator>Hui-Shan Chen</creator><creator>Siao-Chi Wu</creator><creator>Wei-Heng Hung</creator><creator>Heng-Chung Chen</creator><creator>Chang-Lun Huang</creator><creator>Ching-Yuan Cheng</creator><creator>Bing-Yen Wang</creator><general>Public Library of Science (PLoS)</general><scope>DOA</scope></search><sort><creationdate>20220101</creationdate><title>Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma</title><author>Yi-Lin Chang ; Ya-Fu Cheng ; Hui-Shan Chen ; Siao-Chi Wu ; Wei-Heng Hung ; Heng-Chung Chen ; Chang-Lun Huang ; Ching-Yuan Cheng ; Bing-Yen Wang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yi-Lin Chang</creatorcontrib><creatorcontrib>Ya-Fu Cheng</creatorcontrib><creatorcontrib>Hui-Shan Chen</creatorcontrib><creatorcontrib>Siao-Chi Wu</creatorcontrib><creatorcontrib>Wei-Heng Hung</creatorcontrib><creatorcontrib>Heng-Chung Chen</creatorcontrib><creatorcontrib>Chang-Lun Huang</creatorcontrib><creatorcontrib>Ching-Yuan Cheng</creatorcontrib><creatorcontrib>Bing-Yen Wang</creatorcontrib><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yi-Lin Chang</au><au>Ya-Fu Cheng</au><au>Hui-Shan Chen</au><au>Siao-Chi Wu</au><au>Wei-Heng Hung</au><au>Heng-Chung Chen</au><au>Chang-Lun Huang</au><au>Ching-Yuan Cheng</au><au>Bing-Yen Wang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma</atitle><jtitle>PloS one</jtitle><date>2022-01-01</date><risdate>2022</risdate><volume>17</volume><issue>10</issue><eissn>1932-6203</eissn><abstract>Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Results Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p&lt;0.0001). In multivariable analysis, treatment modality was an independent prognostic factor. Esophagectomy with adjuvant chemoradiotherapy provided better survival outcome than definitive chemoradiotherapy for patients with clinical stage II/III disease. As for patients with clinical stage I disease, there was no significant survival difference between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy. Conclusions Esophagectomy with adjuvant chemoradiotherapy provided better survival than definitive chemoradiotherapy in clinical II/III esophageal squamous cell carcinoma. However, more data are needed to conduct a convincing conclusion in clinical stage I patients.</abstract><pub>Public Library of Science (PLoS)</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1932-6203
ispartof PloS one, 2022-01, Vol.17 (10)
issn 1932-6203
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b
source Open Access: PubMed Central; Publicly Available Content Database
title Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A54%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Propensity%20score%20analysis%20comparing%20survival%20between%20definitive%20chemoradiotherapy%20and%20esophagectomy%20with%20adjuvant%20chemoradiotherapy%20in%20patients%20with%20esophageal%20squamous%20cell%20carcinoma&rft.jtitle=PloS%20one&rft.au=Yi-Lin%20Chang&rft.date=2022-01-01&rft.volume=17&rft.issue=10&rft.eissn=1932-6203&rft_id=info:doi/&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-doaj_primary_oai_doaj_org_article_cc4d196e9e094c10b24ba766190ff60b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true